16:45 , Mar 2, 2018 |  BC Week In Review  |  Clinical News

Asana reports Phase Ib data for ASN002 in atopic dermatitis

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from a Phase Ib trial showing that atopic dermatitis candidate ASN002 was well tolerated. The most common adverse events reported were transient, mild headache and nausea. The...
05:09 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

Asana reports Phase I/II data for SYK/JAK inhibitor ASN002 to treat cancer

Asana BioSciences LLC (Lawrenceville, N.J.) reported data from 36 patients with non-Hodgkin’s lymphoma (NHL) or advanced solid tumors in the dose-escalation Phase I portion of a Phase I/II trial showing that oral ASN002 was well...